A groundbreaking new maternal blood test, capable of identifying thousands of serious genetic conditions in a developing foetus, could transform prenatal screening and potentially reduce the need for invasive diagnostic procedures. The technique, known as non-invasive foetal sequencing (NIFS), was developed by scientists at the Broad Institute of Massachusetts Institute of Technology and Harvard University and is set to be presented at the European Society for Human Genetics conference in Gothenburg.
The test operates by analysing tiny fragments of the foetus's DNA, which naturally circulate in the mother's bloodstream during pregnancy. By employing advanced sequencing and computational methods, researchers were able to detect a vast array of genetic conditions, including cystic fibrosis, Noonan syndrome, Charge syndrome, and achondroplasia. Currently, many of these conditions are only reliably diagnosed through invasive methods such as amniocentesis or chorionic villus sampling (CVS), which carry a small but significant risk of miscarriage.
Dr Christopher Whelan, a senior computational scientist involved in the research, stated that the NIFS test is capable of detecting thousands of serious genetic conditions, encompassing most conditions found on major newborn sequencing and foetal anomaly panels, such as the 2,500-gene Genomics England foetal anomalies panel. He envisions this test as a primary screening tool, particularly when an anomaly is detected during an ultrasound or other initial screening. Many expectant mothers currently decline invasive tests due to the associated risks, stress, accessibility issues, and cost, despite their high diagnostic accuracy.
In a validation study, NIFS was applied to 565 pregnancies, with an average gestation of 17 weeks. By sequencing DNA fragments across nearly 23,000 genes in each foetus, the researchers found that their test identified between 95% and 99% of genetic variants discovered by invasive methods, and over 97% of clinically relevant variants. These findings, while promising, are yet to be peer-reviewed, as the presentation is at a conference.
Professor Alexandre Reymond from the University of Lausanne, who was not involved in the study, lauded the achievement as a "tour de force," suggesting it could revolutionise reproductive medicine by opening up new avenues for treatment and prevention. Professor Angus Clarke, a clinical geneticist at Cardiff University, also praised the work as a "very impressive technical feat," particularly for cases where early diagnosis could lead to prenatal treatment. However, Professor Clarke also raised concerns about the potential for incidental findings of unknown significance, which could cause considerable anxiety for parents and lead to unnecessary medical interventions for babies.
While non-invasive blood tests for foetal DNA have already transformed prenatal diagnostics for conditions like Down's syndrome, this new development significantly expands the range of detectable conditions, potentially including almost all genetic conditions currently screened for in newborns. The broader application of NIFS could offer a safer and equally accurate screening option for many pregnancies across the UK, though ethical considerations regarding extensive screening will need careful consideration.